Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment

Journal of Allergy and Clinical Immunology

Volumn 122, Issue 5, 2008, Pages 992-1000

  Murata, Junko ^a   Abe, Riichiro ^a   Shimizu, Hiroshi ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Soluble Fas ligand; Stevens Johnson syndrome; toxic epidermal necrolysis

Indexed keywords

BETAMETHASONE; CD40 LIGAND; FAS LIGAND; GAMMA INTERFERON; HYDROCORTISONE SODIUM SUCCINATE; IMMUNOGLOBULIN; INTERLEUKIN 6; METHYLPREDNISOLONE; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; JAPAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHILD; EPIDERMAL NECROLYSIS, TOXIC; FAS LIGAND PROTEIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MUCOUS MEMBRANE; PREDICTIVE VALUE OF TESTS; SKIN; STEVENS-JOHNSON SYNDROME; YOUNG ADULT;

EID: 55549124179     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2008.06.013     Document Type: Article

References (24)

1. Becker D.S. Toxic epidermal necrolysis. Lancet 351 (1998) 1417-1420
2. Roujeau J.-C., Kelly J.P., Naldi L., Rzany B., Stern R.S., Anderson T., et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 333 (1995) 1600-1608
3. Bastuji-Garin S., Rzany B., Stern R.S., Shear N.H., Naldi L., and Roujeau J.C. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 129 (1993) 92-96
4. Rzany B., Mockenhaupt M., Baur S., Schroder W., Stocker U., Mueller J., et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol 49 (1996) 769-773
5. Luther J., and Glesby M.J. dermatologic adverse effects of antiretroviral therapy: recognition and management. Am J Clin Dermatol 8 (2007) 221-233
6. Wolkenstein P., Latarjet J., Roujeau J.-C., Duguet C., Boudeau S., Vaillant L., et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 352 (1998) 1586
7. Caproni M., Antiga E., Parodi A., Schena D., Marzano A., Quaglino P., et al. Elevated circulating CD40 ligand in patients with erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. Br J Dermatol 154 (2006) 1006-1007
8. al-Janadi M., al-Balla S., al-Dalaan A., and Raziuddin S. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J Clin Immunol 13 (1993) 58-67
9. Sekiyama K.D., Yoshiba M., and Thomson A.W. Circulating proinflammatory cytokines (IL-1 beta, TNF-alpha, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis. Clin Exp Immunol 98 (1994) 71-77
10. Viard I., Wehrli P., Bullani R., Schneider P., Holler N., Salomon D., et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282 (1998) 490-493
11. Abe R., Shimizu T., Shibaki A., Nakamura H., Watanabe H., and Shimizu H. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol 162 (2003) 1515-1520
12. Mizutani Y., Hongo F., Sato N., Ogawa O., Yoshida O., and Miki T. Significance of serum soluble Fas ligand in patients with bladder carcinoma. Cancer 92 (2001) 287-293
13. Das H., Imoto S., Murayama T., Kajimoto K., Sugimoto T., Isobe T., et al. Levels of soluble FasL and FasL gene expression during the development of graft-versus-host disease in DLT-treated patients. Br J Haematol 104 (1999) 795-800
14. Hein O., Misterek K., Tessmann J.-P., van Dossow V., Krimphove M., and Spies C. Time course of endothelial damage in septic shock: prediction of outcome. Crit Care 9 (2005) R323-R330
15. Stur K., Karlhofer F.M., and Stingl G. Soluble FAS ligand: a discriminating feature between drug-induced skin eruptions and viral exanthemas. J Invest Dermatol 127 (2007) 802-807
16. Chung W.-H., Hung S.-I., Hong H.-S., Hsih M.-S., Yang L.-C., Ho H.-C., et al. Medical genetics A marker for Stevens-Johnson syndrome. Nature 428 (2004) 486
17. *1502-bound peptides: Implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 120 (2007) 870-877
18. Dainichi T., Uchi H., Moroi Y., and Furue M. Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity?. Dermatology 215 (2007) 86-88
19. *0206 and Stevens-Johnson syndrome in the Japanese. Am J Ophthalmol 143 (2007) 367-368
20. Lee J.Y., Chae D.W., Kim S.M., Nam E.S., Jang M.K., Lee J.H., et al. Expression of FasL and perforin/granzyme B mRNA in chronic hepatitis B virus infection. J Viral Hepat 11 (2004) 130-135
21. Takada S., Hatsumi N., Saito T., Matsushima T., Sakura T., Tamura J., et al. Two cases of chronic graft-versus-host disease with elevated levels of soluble Fas ligand in serum. Am J Hematol 64 (2000) 133-136
22. Chen D.Y., Hsieh T.Y., Hsieh C.W., Lin F.J., and Lan J.L. Increased apoptosis of peripheral blood lymphocytes and its association with interleukin-18 in patients with active untreated adult-onset Still's disease. Arthritis Rheum 57 (2007) 1530-1538
23. Tomokuni A., Otsuki T., Isozaki Y., Kita S., Ueki H., Kusaka M., et al. Serum levels of soluble Fas ligand in patients with silicosis. Clin Exp Immunol 118 (1999) 441-444
24. Nozawa K., Kayagaki N., Tokano Y., Yagita H., Okumura K., and Hasimoto H. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum 40 (1997) 1126-1129